Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.55 |
| ▸ | IKBKB | O14920 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.43 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.43 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.43 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.43 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21603259 | 0.91 | PRKCZ (0.55) | ROCK1PRKCZROCK2PRKACAPRKG1 | |
| SCHEMBL12093734 | 0.85 | GRM5 (0.45) | ROCK1ROCK2DYRK1AKCNH2 | |
| SCHEMBL12247661 | 0.85 | GRM5 (0.45) | DYRK1A | |
| SCHEMBL13791457 | 0.83 | GRM5 (0.46) | — | |
| SCHEMBL31656568 | 0.83 | SLC6A2 (0.49) | ROCK1PRKCZROCK2DYRK1AKCNH2 | |
| SCHEMBL23839561 | 0.82 | LNPEP (0.45) | — | |
| SCHEMBL20281696 | 0.82 | ROCK1 (0.58) | ROCK1IKBKBPRKCZROCK2PRKCD | |
| SCHEMBL20779755 | 0.81 | ROCK1 (0.52) | ROCK1IKBKBHRH1PRKCZROCK2 | |
| SCHEMBL21999270 | 0.81 | ROCK1 (0.62) | ROCK1IKBKBHRH1PRKCZROCK2 | |
| SCHEMBL12510759 | 0.81 | GRM5 (0.48) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| WO-2019243530-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-8987276-B2 | Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987276-B2 | Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140011816-A1 | NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-09 | — | — | US | disclosed |
| US-20140011816-A1 | NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-09 | — | — | US | disclosed |
| WO-2012126984-A1 | NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | ROCK1 4324/4885IKBKB 2508/4885HRH1 3096/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | ROCK1 2870/4885IKBKB 2638/4885HRH1 455/4885 |
| US-20140011816-A1 | NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ROCK1 2577/4885IKBKB 741/4885HRH1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.